<?xml version="1.0" encoding="UTF-8"?>
<p>The use of immunosuppressive drugs such as biological disease-modifying antirheumatic drugs (bDMARDs) is often applied in rheumatological diseases. Despite the benefit of the use of bDMARDs, these drugs are known to have immunomodulatory and immunosuppressive effects, predisposing the users to an increased risk of infections and their complications by viruses such as cytomegalovirus (CMV), varicella zoster virus, Epstein-Barr virus, hepatitis B virus, and influenza virus [
 <xref rid="B8" ref-type="bibr">8</xref>–
 <xref rid="B10" ref-type="bibr">10</xref>]. On the other hand, bDMARDs have the potential to block inflammatory cytokines, can reduce the inflammatory process in tissues induced by viral infection, and may have benefits in the outcome of some diseases that have a chronic pattern, such as chikungunya fever [
 <xref rid="B11" ref-type="bibr">11</xref>–
 <xref rid="B13" ref-type="bibr">13</xref>].
</p>
